Clinical trial · Observational
A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan
NCT01752075CI-TRIAL-00041725completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The REVLIMID Registry will provide safety data from a large cohort of Taiwanese patients treated with REVLIMID. In addition, the registry will provide efficacy data and outcomes in a real-world setting (versus a clinical trial).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Revlimid | Drug | Lenalidomide | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- REVLIMID
- description
- Taiwanese patients treated with REVLIMID
- interventionNames
- Drug: Revlimid
Primary outcomes (1)
- measure
- Adverse Events
- timeFrame
- Up to two years
- description
- Number of participants with adverse events
Secondary outcomes (1)
- measure
- Efficacy
- timeFrame
- Up to two years
- description
- Revlimid dosage, reason for Revlimid discontinuation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients 18 years of age or older * Patients that are being prescribed REVLIMID in combination with dexamethasone for the treatment of multiple myeloma and that have received at least one prior therapy * Patient must be willing and able to provide informed consent * Patients will be informed about the Registry and will have to sign a specific Registry Informed Consent Form * Be able to ask questions prior to signing the Subject Information and Consent Form * Be clearly informed that their involvement/participation in the registry is voluntary * Understand that their medical care will not be altered in any way by their participation in the registry Exclusion Criteria: \- A Patient who is unwilling or unable to provide informed consent will not be included.
References
Publications (0)
Data not yet available
No reference posted for this study.